

## **SAFETY DATA SHEETS**

**This SDS packet was issued with item:**

078582720

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078582712 078582738 078582746 078582753 078905626 078926168 078926169 078926170 078926171 078926172

078926173

**Comfortis Chewable Tablets**

Version 2.1

Revision Date 11/24/2009

Print Date 03/02/2010

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Comfortis Chewable Tablets  
Substance Number : 000004278221  
Common Name : Comfortis Chewable Tablets

Company : Elanco Animal Health  
Division of Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, IN 46285

Telephone : 1-888-767-5023  
Emergency telephone : CHEMTREC: 1-800-424-9300 (Outside U.S. 1-703-527-3887)

Item Code : CA4223, CA4224, CA4225, CA4227, CA4222, CA4229, CA4230, CA4231

**SECTION 2. HAZARDS IDENTIFICATION****Emergency Overview****Lilly Lab Labeling Code****Health:** 1**Fire:** 1**Reactivity:** 0**Primary Hazards:** Not hazardous if intact, Liver, Kidney, Bone Marrow**Hazard Summary (Caution):** Effects of exposure to contents: May cause liver effects. May cause kidney effects. May cause bone marrow effects.**Emergency Overview**

Form : tablet  
Colour : tan to brown  
Odour : Roast beef and liver

**Potential Health Effects**

Eyes : Effects of exposure to contents: May cause mild or transient irritation.

Aggravated Medical Condition : None known.

**Comfortis Chewable Tablets**

Version 2.1

Revision Date 11/24/2009

Print Date 03/02/2010

Primary Routes of Entry : Skin contact

Additional Information : This product is intended for animal consumption under guidance of a veterinarian. Exposure to small amounts during normal handling is not likely to cause harmful effects. Animal studies have reported the following effects: Liver effects. Kidney effects. Bone marrow changes. (spinosad)

**Carcinogenicity**

NTP No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

IARC No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Chemical Name	CAS-No.	Concentration [%]
Spinosad	168316-95-8	57 - 60
Spinosyn A	131929-60-7	
Spinosyn D	131929-63-0	
Excipients	NA	40 - 43

NA = Not applicable, Not assigned, or Not available.

**SECTION 4. FIRST AID MEASURES**

General advice : Intact capsules or tablets are not considered hazardous under normal handling procedures.

Inhalation : If crushed and exposure to content occurs: Remove to fresh air. Consult a physician after significant exposure.

Skin contact : Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact : If crushed and exposure to content occurs: Immediately flush eye(s) with plenty of water. Obtain medical attention.

Ingestion : If conscious, give the victim plenty of water to drink. Never give anything by mouth to an unconscious person. Call a physician immediately.

**SECTION 5. FIRE-FIGHTING MEASURES**

Flash point : not applicable

Lower explosion limit : no data available

**Comfortis Chewable Tablets**

Version 2.1

Revision Date 11/24/2009

Print Date 03/02/2010

Upper explosion limit : no data available

Suitable extinguishing media : Water Carbon dioxide (CO<sub>2</sub>) Dry chemical

Unusual Fire and Explosion Hazard. : Hazardous decomposition products formed under fire conditions.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Methods for cleaning up : Clean up promptly by sweeping or vacuum. The following are recommended for manufacturing or other situations where exposure to contents may occur. Wear protective equipment, including eye protection, to avoid exposure (see Section 8 for specific handling precautions).

**SECTION 7. HANDLING AND STORAGE****Handling**

Advice on safe handling : NOT FOR HUMAN USE! Keep out of the reach of children.

**Storage**

Requirements for storage areas and containers : Store at 20 to 25 C (68 to 77 F). Excursions permitted from 15 to 30 C (59 to 86 F).

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Exposure guidelines**

Components	Exposure Limit Values
Spinosad	<b>Supplier:</b> TWA 0.3 mg/m <sup>3</sup>

The following are recommended for manufacturing or other situations where exposure to contents may occur.

**Personal protective equipment**

Respiratory protection : Use an approved respirator.

Eye protection : Safety glasses

Skin and body protection : Chemical-resistant gloves and impermeable body covering to minimize skin contact. If

**Comfortis Chewable Tablets**

Version 2.1

Revision Date 11/24/2009

Print Date 03/02/2010

handled in a ventilated enclosure, as in a laboratory setting, respirator and goggles or face shield may not be required. Safety glasses are always required.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES****Appearance**

Form	: tablet	Colour	: tan to brown
Physical state	: solid	Odour	: Roast beef and liver

**Safety data**

Flash point	: not applicable	Upper explosion limit	: no data available
Lower explosion limit	: no data available	Water solubility	: no data available

**SECTION 10. STABILITY AND REACTIVITY**

Materials to avoid	: Strong oxidizing agents
Hazardous decomposition products	: Hazardous decomposition products formed under fire conditions.
Thermal decomposition	: Stable under normal conditions.
Hazardous reactions	: Hazardous polymerisation does not occur.

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute oral toxicity**

• Spinosad:	LD50 (male rat) 4,444 mg/kg
	LD50 (female rat) > 5,000 mg/kg
	LDLo (dog) > 400 mg/kg

**Acute inhalation toxicity**

• Spinosad:	LC50 (rat) > 5,180 mg/m3 (4 h)
-------------	--------------------------------

**Acute dermal toxicity**

• Spinosad:	LD50 (rabbit) > 5,000 mg/kg
-------------	-----------------------------

**Skin irritation**

• Spinosad:	rabbit, No irritation
-------------	-----------------------

**Eye irritation**

• Spinosad:	rabbit, slight irritation
-------------	---------------------------

**Comfortis Chewable Tablets**

Version 2.1

Revision Date 11/24/2009

Print Date 03/02/2010

**Sensitisation**

- Spinosad: guinea pig, Did not cause sensitization on laboratory animals.

**Repeated dose toxicity**

- Spinosad: In animals, has been shown to cause vacuolation of cells in liver, kidney, and bone tissues and changes in blood and serum biochemistry. Dose levels producing these effects were many times higher than any dose levels expected from exposure due to use.

**Carcinogenicity**

- Spinosad: Animal testing did not show any carcinogenic effects.

**Reproductive toxicity**

- Spinosad: In laboratory animal studies, effects on reproduction have been seen only at doses that produced significant toxicity to the parent animals.

**Mutagenicity**

- Spinosad: Result in genetic toxicity assays (in vitro and in vivo): Negative.

**SECTION 12. ECOLOGICAL INFORMATION****Toxicity to fish**

- Spinosad LC50 / 96 h / *Lepomis macrochirus*: 5.94 mg/l  
LC50 / 96 h / *Oncorhynchus mykiss*: 30 mg/l

**Toxicity to algae**

- Spinosad EC50 / *Pseudokirchneriella subcapitata*: >105.5 ppm  
EC50 / *Navicula* sp.: 0.107 mg/l

**Toxicity to daphnia**

- Spinosad EC50 / 48 h/ *Daphnia magna* : 92.7 mg/l

**SECTION 13. DISPOSAL CONSIDERATIONS**

Waste disposal methods : In accordance with local and national regulations.

**SECTION 14. TRANSPORT INFORMATION**

<b>IMDG</b>	UN Number	: 3077
	Description of the goods	: Environmentally hazardous substance, solid, n.o.s. (Spinosad)
	Class	: 9
	Packaging group	: III
	Labels	: 9
	Marine pollutant	: yes

**Comfortis Chewable Tablets**

Version 2.1

Revision Date 11/24/2009

Print Date 03/02/2010

Other information : Not dangerous goods in the meaning of DOT.

**SECTION 15. REGULATORY INFORMATION**

**TSCA Status:** Not On TSCA Inventory

131929-60-7 Spinosyn A  
131929-63-0 Spinosyn D

**DSL Status:** This product contains the following components that are not on the Canadian DSL nor NDSL lists.

131929-60-7 Spinosyn A  
131929-63-0 Spinosyn D  
Excipients  
168316-95-8 Spinosad

**California Prop. 65**

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

**US. EPA Emergency Planning and Community Right-To-Know Act (EPCRA) SARA Title III Section 313 Toxic Chemicals (40 CFR 372.65) - Supplier Notification Required**

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US. EPA Emergency Planning and Community Right-To-Know Act (EPCRA) SARA Title III Section 302 Extremely Hazardous Substance (40 CFR 355, Appendix A)**

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

**SECTION 16. OTHER INFORMATION**

**Further information**

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:  
Elanco Companion Animal Health  
1-888-545-5973